This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) strong product line.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
BD's (BDX) New Robotic Track System to Boost Lab Workflow
by Zacks Equity Research
BD's (BDX) new robotic track system for the BD Kiestra microbiology laboratory solution is expected to streamline lab workflows.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Within Abbott's (ABT) Established Pharmaceuticals Division (EPD), new product launches across key markets have been majorly boosting business in recent months.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growing adoption of Panther instruments and growth in the Surgical business will likely drive Hologic's (HOLX) Q1 revenues.
DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.
Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology
by Zacks Equity Research
Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.
Intuitive Surgical (ISRG) Reports Mixed Preliminary Q4 Revenues
by Zacks Equity Research
Intuitive Surgical's (ISRG) revenue growth in the fourth quarter is driven by increase in procedure volume, partially offset by resurgence of COVID-19 in China.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Inogen (INGN) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its product sales.
Cardinal Health (CAH) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $76.52 in the latest trading session, marking no change from the prior day.
PacBio's (PACB) Preliminary Q4 Revenues Dampened by Lower Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.
Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.
Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Cardinal Health, Inc. (CAH) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.
DexCom (DXCM) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its CGM sales.
Here's Why You Should Retain Veradigm (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Veradigm (MDRX) owing to its strategic alliances.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health (CAH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cardinal Health (CAH) closed at $77.57, marking a -1.36% move from the previous day.
The Zacks Analyst Blog Highlights Cardinal Health, Conagra Brands, Ingredion, Atmos Energy and NRG Energy
by Zacks Equity Research
Cardinal Health, Conagra Brands, Ingredion, Atmos Energy and NRG Energy are included in this Analyst Blog.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
QuidelOrtho (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.
Baxter (BAX) Plans to Form Standalone Kidney Care Company
by Zacks Equity Research
Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.
2 Dividend Aristocrat Stocks to Buy and Never Sell
by Ethan Feller
Dividend Aristocrats are steady and maybe a bit boring. But that can be a good thing, especially during periods of volatility
Looking for a Growth Stock? 3 Reasons Why Cardinal (CAH) is a Solid Choice
by Zacks Equity Research
Cardinal (CAH) could produce exceptional returns because of its solid growth attributes.